ISEE Profile
IVERIC bio Inc. (ISEE) is a biopharmaceutical company that focuses on discovering and developing novel therapies to treat ophthalmic diseases. The company's lead product candidate, Zimura, is a complement factor C5 inhibitor being developed for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) and autosomal recessive Stargardt disease (STGD1). The company also has a pipeline of other preclinical and clinical-stage candidates for the treatment of ophthalmic diseases, including gene therapies for inherited retinal diseases. IVERIC bio is headquartered in New York City and was founded in 2013.
|
